Alvotech (Buy, TP: USD21.00) - First quarter as a listed company
H1 earnings were in line with our expectations, adjusted for one-off items. The focus in H2 will be on the sales trend for AVT02 (Humira biosimilar) in Europe and the progress of its filing in the US, as well as other pipeline developments. Thus far, we believe the company has delivered on its pipeline. Hence, we reiterate our BUY and USD21 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.